Approval is not access: Pilots’ real test is implementation
The UK’s medicines access pilots should be welcomed as a serious attempt to address a long-standing problem: how to bring promising medicines into routine use faster while preserving evidence standards, value for money, and clinical independence. But the pilots should not be judged by announcement language, selection speed, or even the existence of a positive national decision alone.
Their real test is implementation.
In medicines policy, the word approval can hide several different steps. MHRA marketing authorisation addresses whether a medicine can be supplied, based on quality, safety, efficacy, and benefit-risk. NICE recommendation addresses whether it should be funded for NHS use in England, based on clinical and cost-effectiveness. Local adoption is a further question: whether the service has the pathway, diagnostic capacity, workforce, pharmacy process, data flow, and governance needed to offer the medicine to eligible patients in practice.
The pilots sit in that difficult space between national decision-making and patient-level delivery. That is where access often becomes real, delayed, uneven, or invisible.
The issue is not the absence of a statutory access duty. NICE-recommended medicines already carry a funding obligation within defined timelines, unless otherwise specified. The harder question is whether that obligation is visibly operationalised through funded pathways, service capacity, and measurable uptake among eligible patients. A medicine can be nationally recommended and still be difficult to access if local systems are not ready to identify, offer, deliver, and monitor it.
Pilots need to be judged against four practical tests
Time from recommendation to funded pathway availability.
The question should not simply be: how quickly can the first patient be treated? That can be a useful signal, but it is not sufficient proof of access. One specialist centre treating one patient does not mean the wider system is ready. A better measure is how long it takes from final guidance to local availability without additional restrictions: formulary inclusion, pathway publication, clinician awareness, pharmacy readiness, and the first eligible patients being offered the option where clinically appropriate.
The pilots should also track the distance between recommendation and routine use. How long until eligible patients are being identified? How long until the medicine is embedded into referral flows? How long until uptake reflects the expected eligible population, adjusted for indication, prevalence, clinical setting, and local service configuration? These are less headline-friendly metrics, but they are closer to the real access question.
Regional variance.
If access depends materially on where a patient lives, then national recommendation has not fully translated into equitable adoption. But regional data must be handled carefully. Variation is not automatically inequity. Uptake can differ because of disease prevalence, specialist centre concentration, diagnostic coding, pathway maturity, clinical choice, patient preference, and data completeness.
The answer is not crude league tables. The answer is transparent, adjusted measurement. Regional uptake should be compared against the expected eligible population and interpreted alongside diagnostic capacity, provider configuration, and pathway readiness. Otherwise, the system risks either missing genuine access gaps or unfairly blaming local teams for variation they cannot control.
Diagnostic and pathway readiness.
Some medicines do not only require a prescription decision. They require earlier identification, testing, specialist assessment, infusion or administration capacity, monitoring, follow-up, and sometimes service redesign. A recommendation without a funded clinic slot, diagnostic route, pharmacy process, and follow-up model is availability on paper, not operational access.
This is where the pilots can add real value. They should ask readiness questions before implementation, not discover the problem after guidance is published. Which patients are eligible? How will they be found? Which test confirms eligibility? Who pays for that test? Which clinic owns the pathway? What happens when demand rises? What data will show whether eligible patients are moving through the pathway, rather than dropping out between referral, diagnosis, and treatment?
For patients, adoption is not an abstract uptake curve. It is whether they are identified, informed, offered the option, and treated through a pathway that works in their region. That requires practical design, not only policy intent.
Governance of industry co-investment.
The recent policy direction recognises that industry may have a role in supporting screening, testing, and parts of the care journey. That should not be dismissed. Industry can bring expertise, operational capacity, and investment into areas where the system is under strain. But the legitimacy of that contribution depends entirely on how it is governed.
Adoption metrics and each link matter
The question is not whether industry can contribute. It can. The question is whether contribution is transparent, non-promotional, infrastructure-focused, and independently assessed. Any co-investment model should be prospectively documented, publicly disclosed, time-limited where appropriate, and separated from prescribing, procurement, and patient-data access decisions. It should publish the parties involved, financial arrangements, intended patient or NHS benefit, outcome measures, exit criteria, and results.
Co-investment should never be contingent on prescribing volume, product preference, pathway lock-in, or privileged access to patient data. If these lines are not clear, the pilots risk creating suspicion even where the operational need is legitimate.
There is also a broader economic point. Faster adoption can strengthen the UK’s life sciences environment by making the country a more predictable place to launch, evaluate, and implement medicines. That matters for investment, clinical research, and industry confidence. But predictability for industry cannot be purchased by weakening public value. In a finite NHS budget, faster uptake must remain tied to evidence, affordability, opportunity cost, and transparent decisions about what is displaced when new spending is prioritised.
This is why adoption metrics matter. They should not be used simply to push volume. They should be used to understand whether a medicine that has passed the relevant evidence and value tests is actually becoming available through functioning, equitable pathways. Good adoption measurement protects patients, clinicians, commissioners, and industry because it replaces rhetoric with evidence.
The pilots therefore need a clear implementation scorecard. It should distinguish between regulatory authorisation, NICE recommendation, funded local availability, clinical offering, patient uptake, and outcome monitoring. It should show where delay occurs: evidence generation, appraisal, commissioning, diagnostics, pathway design, workforce, procurement, data capture, or patient identification. Without that granularity, the system may celebrate speed at the front end while leaving adoption gaps unresolved at the point of care.
The strongest version of these pilots would not treat access as a press release milestone. It would treat access as a delivery chain. Each link matters: licensing, recommendation, funding, pathway readiness, clinician confidence, diagnostic capacity, patient identification, administration, monitoring, and transparent governance.
Approval is the start of the access test, not the end. A medicine that is nationally recommended, but unevenly adopted, is still not meaningful access. If the pilots can measure and close the gap between recommendation and real-world use, they will do more than accelerate decisions. They will show whether the UK can turn life sciences ambition into dependable patient-level delivery.
About the author
Varun Sharma is the founder of NEUVIOR, a pharmaceutical technology company focused on healthcare innovation and implementation. He writes on medicines access, adoption, and the practical delivery of healthcare innovation.
